Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Triple-Negative Breast Cancer Drug Treatment Study
This randomized phase III trial studies how well experimental drug MK-3475 (also called pembrolizumab) works in treating triple-negative breast cancer. The purpose of this study is to compare the usual approach (example: no more treatment additional post-operative chemotherapy), to any effects, good and/or bad, of pembrolizumab after surgery. This study will allow the researchers to know whether treatment with pembrolizumab is better, the same, or worse than the usual approach.
In order to participate you must meet the following criteria:
- Have confirmed estrogen receptor (ER)-, progesterone receptor (PR)- and HER2-negative (triple-negative, TNBC) with residual invasive breast cancer.
- Have had neoadjuvant chemotherapy followed by surgery.
- Have completed your final breast surgery (rendering you free from disease) prior to screening registration.
You will be excluded from the study if any of the following criteria apply to you:
- Have metastatic disease.
- Have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs.
- Have active autoimmune disease that has required systemic treatment in past 2 years. (Replacement therapy is not considered a form of systemic treatment.)
This is a partial list of inclusion and exclusion criteria.